



pharmacological perspectives from biology, chemistry and genomics

April 2007 Volume 7, Issue 2 www.molinterv.org

DEPARTMENTS

56 Speaking of Pharmacology

Harry B. Smith

59 Reflections

Medicine in the Days of the Caliphs Stanley Scheindlin

65 Nascent Transcripts

Emerging concepts from the recent literature

66 Significant Deciles

ASPET celebrates its centennial anniversary

112 Beyond the Bench

Telescopic Hindsight Christie Carrico

114 NetResults

Sites of Interest on the World Wide Web

115 Professional Opportunities

Position Openings

117 On Deck

Upcoming Meetings

120 Outliers

mi cartoon



EDITOR

Harry B. Smith

ASSOCIATE EDITOR

John W. Nelson

DESIGN & LAYOUT

Vizuäl, Inc.

EDITORIAL ADVISORY BOARD

John S. Lazo, Chair, U Pittsburg Darrell R. Abernethy, NIH/NIA Susan Amara, *U Pittsburgh* Leslie Z. Benet, *UCSF* Joan Heller Brown, UCSD Bryan Cox, *Abbott*Raymond Dingledine, *Emory U*Sue Duckles, *UC Irvine* Alfred G. Gilman, U Texas SW Randy Hall, Emory U
Ken Harden, U North Carolina
John Hickman, Servier
Dayle Houston*, U North Carolina
Robert S. Kass, Columbia U
Serrine S. Lau, U Arizona
Rebebble Laga, NUCAS (2011) Rochelle Long, NIGMS/NIH Benedict Lucchesi, *U Michigan* Kenneth P. Minneman, *Emory U* Perry Molinoff, *U Pennsylvania* Perry Molinoff, U Pennsylvania Richard R. Neubig, U Michigan Stefan Offermanns, U Heidelberg Carlo Patrono, U Rome David Roman**, U Michigan Alan Sartorelli, Yale U Boris Tabakoff, U Colorado Palmer Taylor, U San Diego Robert Tomko*, U Pittsburgh Ted Torphy, Johnson&Johnson Roger Tsien, UCSD Michael R. Vasko, U Indiana Mary Vore, U Kentucky Mary Vore, *U Kentucky* Richard M. Weinshilboum, *Mayo*

* Student representative; ** Postdoctoral representative

BOARD OF PUBLICATIONS TRUSTEES

Brian M. Cox Darrell R. Abernethy P. Jeffrey Conn Lorraine Gudas Eric F. Johnson John S. Lazo Edward T. Morgan Richard R. Neubig Rick G. Schnellmann Darryle D. Schoepp Mary Vore

EXECUTIVE OFFICER Christine K. Carrico

JOURNALS DIRECTOR

Richard Dodenhoff

Hichard Dodenhort

Molecular Interventions (ISSN 1534-0384) is published by the

American Society for Pharmacology and Experimental Therapeutics,
9550 Rockville Pike, Bethesda, MD 20814-3995. Published bimonthly in
February, April, June, August, October, and December. Annual subscription rates: U.S.: \$240 for institutions and \$98 for individuals. Outside
the U.S.: \$261 for institutions and \$99 for individuals. The subscription
price to ASPET members (\$30) is included in membership dues. Single
issue: \$44. Subscriptions include access to the online version of M/at molinterv.org (ISSN 1543-2548). Indexed or abstracted by Biochemistry & Biophysics Citation Index, EMBASE/Excerpta Medica, Index to

a Biophysics citation fines, Eviboacy Except a Weblad, flock to Science, PubMed/Medline, and Science Citation Index-Expanded.

Advertising (FASEB AdNet): 301-634-7103; adnet@faseb.org.

Editorial: 301-634-7790; mi@aspet.org. Subscriptions: 301-634-7099; staff@dues.faseb.org. ASPET: 301-634-7099; info@aspet.org.

Statements and opinions contained in the articles of Molecular International Control of the Aspect of Molecular International Control of the Aspect of Molecular International Control of Contro

Interventions are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics. The appearance of advertisements in Molecular Interventions is not a warranty, endorsement, or approval of the products or their safety. The American Society for Pharmacology and Experimental Therapeutics disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

the articles or advertisements.

Molecular Interventions is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. Photocopying of articles beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law is allowed, provided that the \$20.00 per-copy fee is paid through the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. Classroom photocopying is permitted at no fee, provided that students are not charged more than the cost of duplication. This consent does not extend to other kinds of copying, Beproduction of any portion of an article for subsequent republication requires permission of the copyright owner. Write to ASPET Copyright Dept., 9650 Rockville Pike, Bethesda, MD 20814-3995. MD 20814-3995

Postmaster: Send address changes to Molecular Interventions, ASPET, 9650 Rockville Pike, Bethesda, MD 20814-3995.



malecular interventions


pharmacological perspectives from biology, chemistry and genomics

VIEWPOINTS

68 Male Contraceptives: New Targets, Future Breakthroughs


Blocking sperm motility has great appeal as a male contraceptive. A drug that targets sperm motility might have a very rapid onset of action, possibly allowing for administration immediately prior to intercourse and minimizing concerns about compliance. Promising sperm motility targets include transmembrane calcium channels, a unique adenylyl cyclase, and novel flagellar proteins. Future efforts directed towards effectively antagonizing the activities of these or other such targets will be required to completely impair sperm production, function, or both and create a usable male "pill."

John K. Amory



page 68 Blocking sperm motility and production

70 Targeting Adenylyl Cyclase in Neurotoxicity




page 70 Targeting AC isoforms to ameliorate damage

The use of transgenic animals lacking one or multiple adenylyl cyclase (AC) isoforms has provided significant information on the roles of AC-dependent signaling in the central nervous system. A recent study provides evidence that AC type 1 (AC1) might be important in glutamate-induced neuronal toxicity. However, the absolute AC specificity revealed in this study contrasts earlier work examining other forms of neurodegeneration. Nonetheless, these observations suggest that specific AC isoforms may represent novel targets for the treatment of central nervous system disorders. It is anticipated that such findings will help catalyze new drug discovery efforts to identify small-molecule modulators of individual AC isoforms.

Val J. Watts

74 Polymorphisms and Propensity for Addiction

Discovery and characterization of the functional A118G mu-(μ)-opioid receptor variant led to hypotheses, now in part proven, about its role in alterations of endogenous human physiology and in responses to opioid antagonist administration. Differences in cellular expression levels, ligand binding, and signal transduction for variant receptors have been documented in vitro. Human genetic studies also indicate that individuals carrying one or two copies of the 118G allele may have increased risk for opiate and alcohol addictions and that this polymorphism may also explain some of the variability in success of opioid



page 74 A118G in addiction: An analysis of "variants"

antagonist treatment for alcoholism. Future research will further define the role of the A118G variant in addictive diseases and their treatment, in pain perception and opioid analgesia, and for a myriad of other responses mediated by the μ -opioid receptor.

Mary Jeanne Kreek and K. Steven LaForge






REVIEWS

79 Salamanders Do It. Let's Fall for Regenerative Medicine.

The idea of regenerative medicine has been with us for so long that the concept has been relegated to mythology (think of Prometheus) or to the wildly creative (think of Walt Disney). But the reality is that regenerative biomedicine has begun to show great promise in the laboratory and clinic, and the field may well be poised to revolutionize worldwide healthcare. Cells cultured from the failing organs of patients can be conditioned in "bioreactors" and grown on scaffolds to take on shapes that recapitulate functional organs. "Neo-organs" constructed in this way represent fully immunocompatible resources for




page 79 Tissue-engineered organs

organ implants, and encouraging clinical results with "neobladders" and tissue-engineered vasculature are established in the literature. The demands and opportunities that regenerative medicine places on pharmacology are enormous, from experimental systems on which to test bioactive agents, to the characterization of neo-organs for use in medicine and research.

Karl-Erik Andersson and George J. Christ

87 Molecular Matters of Taste



page 87
"Chewing the food of sweet and bitter fancy...."


Many of the molecular components of the signal transduction pathways underlying taste have been elucidated. In taste buds, the chemosensory receptors for bitter, sweet, and umami (i.e., savory) tastes now are known to be G protein–coupled receptors, whereas salty and sour tastes result from tastant-activation of ion channels. The sense of taste has been investigated for many years using the methods of psychophysics and neurophysiology, and several excellent animal-based taste models are in use. New methods now are being developed for evaluating taste signaling in isolated taste bud and taste cells, and in cells that heterologously express taste receptors and other taste-specific signal transduction proteins.

R. Kyle Palmer

99 Discounting the Role of Inflammation in Drug Availability Could Be Harmful

Membrane transporters play an important role in determining the absorption and activity of many drugs. Intriguingly, inflammation alters the expression and activity of many drug transporters and thereby affects drug absorption and efficacy. The effects of inflammatory conditions on drug transporter regulation and a possible link between differences in drug disposition and inflammation are discussed.

Vanja Petrovic, Shirley Teng, and Micheline Piquette-Miller



page 99 Inflammatory statements: As easy as ABC (and SLC)